

# Victoria N Parikh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4855755/publications.pdf>

Version: 2024-02-01

22  
papers

865  
citations

759233

12  
h-index

713466

21  
g-index

25  
all docs

25  
docs citations

25  
times ranked

1554  
citing authors

#	ARTICLE	IF	CITATIONS
1	The response to cardiac resynchronization therapy in <sc>LMNA</sc> cardiomyopathy. European Journal of Heart Failure, 2022, 24, 685-693.	7.1	7
2	Promise and Peril of Population Genomics for the Development of Genome-First Approaches in Mendelian Cardiovascular Disease. Circulation Genomic and Precision Medicine, 2021, 14, e002964.	3.6	10
3	Arrhythmogenic Cardiomyopathy: Mechanisms, Genetics, and Their Clinical Implications. Current Cardiovascular Risk Reports, 2021, 15, 1.	2.0	2
4	The genetic architecture of Plakophilin 2 cardiomyopathy. Genetics in Medicine, 2021, 23, 1961-1968.	2.4	13
5	Iron Deficiency as a Potential Modulator of Subclinical Deficiencies in Cardiac Performance and Exercise Capacity. Journal of Cardiac Failure, 2021, 27, 822-824.	1.7	2
6	Phenotypic Expression, Natural History, and Risk Stratification of Cardiomyopathy Caused by Filamin C Truncating Variants. Circulation, 2021, 144, 1600-1611.	1.6	43
7	Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. European Heart Journal, 2021, 42, 3932-3944.	2.2	43
8	Patient-Specific Induced Pluripotent Stem Cells Implicate Intrinsic Impaired Contractility in Hypoplastic Left Heart Syndrome. Circulation, 2020, 142, 1605-1608.	1.6	33
9	Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association. Circulation Genomic and Precision Medicine, 2020, 13, e000067.	3.6	200
10	Stretch-Induced Biased Signaling in Angiotensin II Type 1 and Apelin Receptors for the Mediation of Cardiac Contractility and Hypertrophy. Frontiers in Physiology, 2020, 11, 181.	2.8	18
11	Circulating microRNAs as Biomarkers for Sudden Cardiac Death. JACC: Clinical Electrophysiology, 2020, 6, 80-82.	3.2	1
12	Allele-Specific Silencing Ameliorates Restrictive Cardiomyopathy Attributable to a Human Myosin Regulatory Light Chain Mutation. Circulation, 2019, 140, 765-778.	1.6	26
13	Pathological Overlap of Arrhythmogenic Right Ventricular Cardiomyopathy and Cardiac Sarcoidosis. Circulation Genomic and Precision Medicine, 2019, 12, 452-454.	3.6	1
14	Pathologic gene network rewiring implicates PPP1R3A as a central regulator in pressure overload heart failure. Nature Communications, 2019, 10, 2760.	12.8	22
15	Regional Variation in <i>RBM20</i> Causes a Highly Penetrant Arrhythmogenic Cardiomyopathy. Circulation: Heart Failure, 2019, 12, e005371.	3.9	96
16	Apelin and APJ orchestrate complex tissue-specific control of cardiomyocyte hypertrophy and contractility in the hypertrophy-heart failure transition. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 315, H348-H356.	3.2	28
17	Next-Generation Sequencing in Cardiovascular Disease. Circulation, 2017, 135, 406-409.	1.6	33
18	Mind the Gap: Current Challenges and Future State of Heart Failure Care. Canadian Journal of Cardiology, 2017, 33, 1434-1449.	1.7	19

#	ARTICLE	IF	CITATIONS
19	Wrestling the Giant. <i>Circulation: Cardiovascular Genetics</i> , 2016, 9, 392-394.	5.1	3
20	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 236-241.	2.1	12
21	MicroRNA-21 Integrates Pathogenic Signaling to Control Pulmonary Hypertension. <i>Circulation</i> , 2012, 125, 1520-1532.	1.6	246
22	Wnt Signaling Interactor WTIP (Wilms Tumor Interacting Protein) Underlies Novel Mechanism for Cardiac Hypertrophy. <i>Circulation Genomic and Precision Medicine</i> , 0, , .	3.6	0